For related news links, please click to redirect:https://mp.weixin.qq.com/s?__biz=MzIyOTgyODUxNQ==&mid=2247511689&idx=3&sn=6ea7e1dd9ee0f6f08cb9b82ed1379cf6&chksm=e8be5c45dfc9d553ca7f6c3dac1dafc3b9e3ca620b9b3e5fa2cc3ee7d1b59f33e2aa9e894d70&scene=27

https://www.dutenews.com/n/article/8503029

        On November 12th, the "Cross-Border Innovation" Biomedical Science and Technology Innovation Exchange event, organized by the Shenzhen Science and Technology Exchange Service Center and undertaken by Shenzhen Zijingwan Private Equity Investment Fund Management Co., Ltd., was successfully held. The event aimed to establish an international exchange platform to promote in-depth cooperation and technology transfer in the field of biomedical science and technology innovation between Shenzhen and overseas. Numerous experts, scholars, entrepreneurs, and representatives from investment institutions in the biomedical field from both domestic and international spheres attended the event.

        The development of AI technology is driving innovation in the biomedical field. Since its inception, Jiying Technology Co., Ltd. has been dedicated to the application research of artificial intelligence technology in the biomedical field, striving to use advanced scientific and technological methods to improve research efficiency and the intuitiveness of results. At the "Cross-Border Innovation" Biomedical Science and Technology Innovation Exchange event, Jiying Technology's founder, Mr. He Song Qiu, introduced AI robots and gene development and application. By integrating multiple artificial intelligence models, they provide precise screening and diagnosis for early gastrointestinal tumors.